Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study

Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study

The Saudi Food and Drug Authority (SFDA) approved sodium-glucose cotransporter-2 (SGLT2) inhibitors in 2018. The efficacy and safety of empagliflozin (EMPA) have been confirmed in the U.S., Europe, and Japan for patients with type 2 diabetes mellitus (T2DM); however, analogous evidence is lacking fo...

Full description

Bibliographic Details
Main Authors: Fahad M. Althobaiti, Safaa M. Alsanosi, Alaa H. Falemban, Abdullah R. Alzahrani, Salma A. Fataha, Sara O. Salih, Ali M. Alrumaih, Khalid N. Alotaibi, Hazim M. Althobaiti, Saeed S. Al-Ghamdi, Nahla Ayoub
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Journal of Clinical Medicine
Subjects:
empagliflozin
safety
efficacy
Saudi patients
type 2 diabetes mellitus
Online Access:https://www.mdpi.com/2077-0383/11/16/4769

Internet

https://www.mdpi.com/2077-0383/11/16/4769

Similar Items